LAAs more extensively investigated in phase I or II trials are Wilms tumor (WT1), mucin 1 protein (MUC1), proteinase 3 (PR3), and the receptor for hyaluronic acid-mediated motility (RHAMM), which is found overexpressed in >80% of AML patients [88]; based on the results from early trials, the setting that more likely could benefit more from interventions with peptide vaccines is represented by patients in CR or with minimal residual disease. This evidence concerns the gene PRTN3 and acute myeloid leukemia.